Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Potent PTP-1B-targeted antisense therapy enters phase I trial in type 2 diabetes

July 25, 2011

Mochida Pharmaceutical prepares new free fatty acid FFA1 receptor agonists

July 25, 2011

Manhattan Pharmaceuticals and FDA reach agreement on SPA for phase III AST-726 trial

July 22, 2011

Galapagos small-molecule SARM enters proof-of-mechanism phase I trial

July 20, 2011

FDA committee issues opinion on approval of dapagliflozin for type 2 diabetes

July 20, 2011

New estrogen-related receptor-alpha inverse agonists reported

July 20, 2011

Shionogi & Co. presents new endothelial lipase inhibitors

July 20, 2011

Laboratoires Takeda withdraws pioglitazone-containing products from French market

July 18, 2011

Novo Nordisk discloses novel glucagon GLP-1 receptor agonists

July 18, 2011

Evolva completes phase I studies of EV-077

July 15, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...